Key Points
- Kymera Therapeutics CFO Bruce Jacobs sold 77,109 shares on June 30 at an average price of $114.96, totaling about $8.86 million. After the sale, he still held 244,883 shares, a decrease of 23.95% in his ownership.
- The stock was little changed after the disclosure, opening at $113.51 and trading down 0.6% in the session. Kymera now has a market cap of about $9.34 billion and trades well above its 50-day and 200-day moving averages.
- Wall Street remains broadly bullish on KYMR, with 21 Buy ratings, one Strong Buy, and one Sell. The consensus price target is $121.41, and recent analyst upgrades have pushed targets as high as $129.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Noah Goodman sold 3,389 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total transaction of $387,328.81. Following the completion of the transaction, the insider owned 47,179 shares of the company's stock, valued at approximately $5,392,087.91. This trade represents a 6.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Noah Goodman also recently made the following trade(s):
- On Thursday, June 25th, Noah Goodman sold 5,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $114.00, for a total transaction of $570,000.00.
- On Monday, June 22nd, Noah Goodman sold 2,500 shares of Kymera Therapeutics stock. The stock was sold at an average price of $99.00, for a total transaction of $247,500.00.
- On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.00, for a total transaction of $121,230.00.
- On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total transaction of $174,700.00.
- On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total value of $723,100.00.
Kymera Therapeutics Price Performance
Shares of KYMR opened at $113.51 on Friday. The business has a 50-day moving average of $86.87 and a 200-day moving average of $82.91. The company has a market capitalization of $9.34 billion, a price-to-earnings ratio of -31.80 and a beta of 1.95. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $130.05.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.18. The business had revenue of $34.37 million for the quarter, compared to analysts' expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm's revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.82) earnings per share. As a group, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.
Hedge Funds Weigh In On Kymera Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in KYMR. Smartleaf Asset Management LLC grew its stake in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC raised its stake in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after buying an additional 349 shares during the period. Osaic Holdings Inc. raised its stake in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after buying an additional 1,083 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics in the fourth quarter worth approximately $63,000. Finally, Raymond James Financial Inc. bought a new position in Kymera Therapeutics in the second quarter worth approximately $73,000.
Analysts Set New Price Targets
KYMR has been the topic of a number of analyst reports. Brookline Capital Markets reaffirmed a "buy" rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Truist Financial lifted their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday. Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 2nd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Finally, Canaccord Genuity Group upped their price target on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the company a "buy" rating in a research report on Friday, June 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $121.41.
Check Out Our Latest Report on KYMR
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
